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Abstract
Background: Blood eosinophil (B‐Eos) count is an emerging biomarker in the
management of respiratory disease but determinants of B‐Eos count besides res-
piratory disease are poorly described. Therefore, we aimed to evaluate the influence
of non‐respiratory diseases on B‐Eos count, in comparison to the effect on two
other biomarkers: fraction of exhaled nitric oxide (FeNO) and C‐reactive protein
(CRP), and to identify individual characteristics associated with B‐Eos count in
healthy controls.
Methods: Children/adolescents (<18 years) and adults with complete B‐Eos data
from the US National Health and Nutritional Examination Surveys 2005–2016 were
included, and they were divided into having respiratory diseases (n = 3333 and
n = 7,894, respectively) or not having respiratory disease (n = 8944 and n = 15,010,
respectively). After excluding any respiratory disease, the association between B‐
Eos count, FeNO or CRP, and non‐respiratory diseases was analyzed in multivar-
iate models and multicollinearity was tested. After excluding also non‐respiratory
diseases independently associated with B‐Eos count (giving healthy controls;
8944 children/adolescents and 5667 adults), the independent association between
individual characteristics and B‐Eos count was analyzed.
Results: In adults, metabolic syndrome, heart disease or stroke was independently
associated with higher B‐Eos count (12%, 13%, and 15%, respectively), whereas no
associations were found with FeNO or CRP. In healthy controls, male sex or being
obese was associated with higher B‐Eos counts, both in children/adolescents (15%
and 3% higher, respectively) and adults (14% and 19% higher, respectively) (p < 0.01
all). A significant influence of race/ethnicity was also noted, and current smokers
had 17% higher B‐Eos count than never smokers (p < 0.001).
Conclusions: Non‐respiratory diseases influence B‐Eos count but not FeNO or CRP.
Male sex, obesity, certain races/ethnicities, and current smoking are individual
characteristics or exposures that are associated with higher B‐Eos counts. All these
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factors should be considered when using B‐Eos count in the management of res-
piratory disease.
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1 | INTRODUCTION
Airway type‐2 inflammation is a feature of common phenotypes of
asthma1–3 and chronic obstructive pulmonary disease (COPD).4,5 The
most studied biomarkers used to characterize patients with type‐2
inflammation are blood eosinophil (B‐Eos) count and fraction of
exhaled nitric oxide (FeNO).6
In asthma, elevated B‐Eos count is associated with poor disease
control, accelerated lung function decline, increased risk of severe
exacerbations, and re‐hospitalizations.7–11 Also, it has been reported
a dose‐response effect between inhaled corticosteroids (ICS) and the
reduction in B‐Eos levels.12 In COPD patients, higher B‐Eos levels are
associated with an improved response to ICS in preventing exacer-
bations.13–16 During exacerbations, higher B‐Eos levels predict
greater response to oral corticosteroids, while lower levels are
associated with worse outcomes.17,18 Furthermore, exacerbations
are associated with an increased decline in lung function among
COPD patients with elevated B‐Eos and without ICS.18 However, the
overall reported odds ratios are low, and since B‐Eos count could be
significantly influenced by different co‐factors, we suggest that the
association between B‐Eos count and respiratory morbidity could be
improved by adjusting for these factors.
In asthma, persistent type‐2 inflammation indicated by, for
example, elevated FeNO or B‐Eos count, may identify patients with
poor responsiveness to ICS, despite adherence to treatment.19
Furthermore, biomarker‐directed risk stratification to identify pa-
tients suitable for different biological treatments, including FeNO
and B‐Eos count, have been proposed,20,21 and this combination of
biomarkers seems to provide additive predictive information on
asthma morbidity and risk.22,23
FeNO is affected by individual factors such as age, height and
sex,24,25 and cigarette smoke exposure,26 but very few studies have
analyzed possible determinants of B‐Eos count. Nevertheless, indi-
vidual characteristics may also affect B‐Eos values, which could
hamper the clinical interpretation of a B‐Eos count, especially in the
initial assessment of patients with respiratory symptoms. Elevated B‐
Eos levels have been described to be associated with smoking27–29
and increasing age.27,29,30 However, evidence on the influence of
individual factors on B‐Eos count is inconsistent, and even less data
exists for subjects without respiratory disease.27 Moreover, there is a
great controversy regarding the optimal B‐Eos cutoff that is more
strongly associated with various disease outcomes, which could make
the interpretation of a B‐Eos count inconsistent.31
Identification of factors not related to respiratory disease that
should be considered when interpreting a B‐Eos count may be useful
for a targeted and personalized approach in the clinical management
of respiratory diseases. Moreover, in addition to the type of inflam-
mation, its location is also important for the disease assessment. To
this end, it may be necessary to have a comparison with other sys-
temic markers and local type‐2 markers, such as C‐reactive protein
(CRP) and FeNO, respectively.32,33
The aim of this investigation was to (a) evaluate the influence of
non‐respiratory disease on B‐Eos count, FeNO, and CRP, and (b) to
identify individual characteristics that are associated with B‐Eos
count in healthy individuals.
2 | METHODS
2.1 | Data source and study subjects
We analyzed the data publicly available from six 2‐year surveys
(2005–2016) of the National Health and Nutritional Examination
Surveys (NHANES), representing a total of 60,936 individuals from
0 to 85 years old. NHANES is a continuous nationally representative
cross‐sectional survey of civilian noninstitutionalized persons in the
United States of America. Detailed information can be found else-
where.34 The National Center for Health Statistics Research Ethics
Review Board approved the protocols (ERB protocols numbers
#2004‐2005, #2006‐2007, #2008‐2010 and #2011‐2017) and the
participants provided written informed consent.
2.2 | Inflammatory biomarkers
B‐Eos count was analyzed using a quantitative hematologic analyzer
and leukocyte differential cell counter, Beckman Coulter HMX
(Beckman Coulter). Complete details on blood collection procedures,
quality assurance, and control procedures are described elsewhere.35
FeNO was measured following the ATS/ERS recommendations36
using a handheld device with an electrochemical sensor, NIOX MINO
(Aerocrine). FeNO measurements not fulfilling ATS/ERS recommen-
dations were excluded (n = 6178%; 28%). Please see Additional file 1
for detailed exclusion criteria.
Serum CRP was quantified by latex‐enhanced nephelometry
using a Dade Behring Nephelometer II Analyzer System (Dade
Behring Diagnostics Inc.). Further details can be found elsewhere.35
FeNO measurements are currently available only for NHANES
survey years 2007–2012 (n = 19,800), serum CRP is available only in
survey years 2005–2010 (n = 23,680), whereas B‐Eos counts were
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measured during all included surveys (2005–2016; n = 49,992). Thus,
all three markers were available in the 2007–2010 survey years
(n = 20,686).
2.3 | Variables
Demographic characteristics, such as age, sex, race/ethnicity, body
mass index (BMI), and smoking status were analyzed. Two age groups
were defined: children/adolescents (if < 18 years) and adults
(≥18 years).
Race/Ethnicity was categorized as non‐Hispanic white, non‐
Hispanic black, Mexican/Hispanic, and other (multi‐racial). BMI was
categorized according to international recommendations, both for
children/adolescents37 and adults,38 into underweight, normal
weight, overweight, and obese. Smoking status was defined as: never
smokers, current smokers, and former smokers. Children/adolescents
were considered as nonsmokers (see Data S1 for details).
Respiratory diseases were considered when having a self‐reported
diagnosis of asthma and/or hay fever (in children/adolescents), or
self‐reported diagnosis of asthma and/or hay fever, and/or other
respiratory diseases (in adults). Asthma was defined as an affirmative
response to the question “Has a doctor ever told you that you had
asthma?” Hay fever was defined if the subject answered positively to
either: “Has a doctor ever told you that you had hay fever?” or
“During the past 12 months, have you had an episode of hay fever?”
Other respiratory diseases were defined if the subject answered
positively to “Has a doctor or other health professional told you that
you had emphysema and/or chronic bronchitis?”
Healthy control groups were obtained by excluding children/ado-
lescents with any of the respiratory diseases described above. In
adults, healthy controls were obtained by excluding subjects having:
any respiratory disease and at least one of the non‐respiratory dis-
eases (arthritis, heart diseases, stroke, cancer, hypertension, dia-
betes, hypercholesterolemia, and metabolic syndrome) that were
significantly associated with B‐Eos after adjustment for individual
characteristics (see below). Details on the definition of the non‐
respiratory diseases are described in the Data S1.
The two respiratory disease groups were defined as: (a) children/
adolescents with respiratory disease; and (b) adults with respiratory
disease and without any significant non‐respiratory disease associ-
ated with elevated B‐Eos counts (Figure 1).
2.4 | Statistical analysis
Statistical analyses were conducted in Stata/IC 15.1 (Stata Corp), and
a statistical significance level was set at p < 0.05. In all analyses, the
complex multistage sampling and sampling weights were considered
using the svy package.
B‐Eos count and FeNO were log‐transformed because of their
highly skewed distribution and described using geometric means and
95% confidence intervals (GM [95%CI]). Also, we categorized both B‐
Eos count and FeNO measurements by using the most commonly
used cut‐offs.39–41 Simple descriptive statistics were used to describe
the study population. To explore the association between B‐Eos
count and each disease factor we performed multivariate linear
regression modeling. Separate univariate and multivariate models
F I GUR E 1 Flowchart of the National Health and Nutritional Examination Surveys (NHANES) participants. *Respiratory diseases included
previous diagnosis of asthma (n = 1984) and/or hay fever (n = 1349); ¥ Respiratory diseases included previous diagnosis of asthma (n = 4744),
hay fever (n = 3244) and/or other respiratory diseases (emphysema n = 653; chronic bronchitis: n = 1748)
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were built using each biomarker (B‐Eos, FeNO, and CRP) as the
outcome variable. All variables with p < 0.20 were considered for
inclusion in the final model. Adjustments were made for co‐variables:
sex, age, race, smoking status, height, and BMI, and weight instead of
BMI, in all models. Diagnostic for multicollinearity was performed
using the variance inflation factor (VIF) test. A VIF above 5 was
considered to indicate a high degree of correlations among the pre-
dictor variables.42 Coefficients (ß) with 95% confidence intervals
(95% CI) were presented, and the model fit was assessed using the
svygof function. Sensitivity analysis was performed by multiple
imputation of missing values (Figure 1) using the MI command.
Additionally, percentage change was calculated by the ratio between
the amount of change and the original value, multiplied by 100.
To analyze the prevalence of the non‐respiratory disease factors,
we divided age into tertiles (18–35; 36–57; ≥58 years old). Spearman
correlation coefficients were calculated between B‐Eos count and
other markers (FeNO and CRP), in both healthy control and respi-
ratory disease groups (in children/adolescents and adults,
respectively).
3 | RESULTS
3.1 | Participant characteristics
NHANES included a total of 60,936 participants from 2005 to 2016,
and 82% had complete data on B‐Eos count across all ages (Figure 1).
Participant characteristics for children/adolescents and adults,
respectively, are described and compared in Table 1. The proportion
TAB L E 1 Characteristics of the participants with B‐Eos data
available in both age groups and respective comparisons
Children/
adolescents Adults p‐value
Totala 16,958 (21) 33,034 (79) <0.001
Female, n (%) 8242 (49) 16,999 (52) 0.024
Age, mean (sd) 9.7 (4.8) 46.4 (17.4) <0.001
BMI, mean (sd) 20.2 (5.4) 28.8 (6.8) <0.001
BMI, n (%)
Underweight 399 (3) 564 (2) 0.319
Normal 9796 (64) 9557 (30) <0.001
Overweight 2502 (16) 10,549 (33) <0.001
Obesity 3025 (18) 11,924 (36) <0.001
Race/ethnicity, n (%)
Non‐Hispanic White 4635 (54) 14,050 (68) <0.001
Non‐Hispanic Black 4272 (14) 6970 (11) 0.041
Mexican/Hispanic 6318 (23) 8702 (14) <0.001
Others (multiracial) 1733 (8) 3312 (7) 0.196
T A B L E 1 (Continued)
Children/
adolescents Adults p‐value
Smoking status, n (%) N.A. N.A.
Never smoker 17,606 (55)
Current smoker 6549 (21)
Former smoker 7397 (24)
Respiratory diseases, n
(%)
3333 (29) 7894 (37) <0.001
Asthma 2721 (16) 4744 (15) 0.249
Hay fever 1035 (11) 3244 (17) <0.001







Heart diseases 2641 (7)




Metabolic syndrome 10,140 (42)
B‐Eos (/mm3), GM
(95% CI)
198 (194–201) 176 (175–178) <0.001
<300/mm3, n (%) 11,166 (68) 24,613 (74) <0.001
300–500/mm3, n (%) 3604 (20) 6414 (20) 0.954
>500/mm3, n (%) 2188 (12) 2007 (6) <0.001





≥12 years (<12 years)
<25 (<20) ppb, n [%] 13,260 [85] (2042 [85]) 0.998
25–50 (20–35) ppb, n
[%]
2121 [12] (224 [8]) 0.076
> 50 (>35 ppb), n [%] 642 [3] (216 [7]) 0.010
CRP (mg/dl), mean (sd) 0.16 (0.6) 0.40 (0.8) <0.001
<0.1 mg/dl, n (%) 6432 (97) 14,857 (91) <0.001
≥0.1 mg/dl, n (%) 240 (3) 1751 (9) <0.001
Healthy control group, n
(%)
8944 (71) 5667 (63) <0.001
aWith available B‐Eos data. Categorical variables presented as absolute
numbers and proportions weighted for the US population. Data
available for FeNO (children/adolescents: n = 4855; adults: n = 13,650)
and for CRP (children/adolescents; n = 6653; adults: n = 16,512).
Abbreviations: BMI, body mass index; B‐Eos, blood eosinophils levels;
FeNO, fractional exhaled nitric oxide; CRP, C‐reactive protein; GM,
geometric mean; CI, confidence interval. N.A. not applicable, because
data were only collected in adults.
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of females was slightly higher in adults compared to the young group.
Furthermore, the proportion of non‐Hispanic whites was larger
among adults (Table 1). Adults reported significantly more respira-
tory diseases than children/adolescents, mainly due to the reporting
of chronic bronchitis and emphysema as well as more hay fever,
whereas the proportion reporting asthma was similar in the two age
groups (Table 1). Children/adolescents showed higher B‐Eos counts
(12%), whereas adults presented with higher FeNO (13%) and CRP
levels (150%).
3.2 | Effect of non‐respiratory diseases on B‐Eos
count
In adults without respiratory disease (Figure 1), the prevalence of all
the non‐respiratory disease factors across age tertiles is shown in
Table S1. Univariate analyses showed that B‐Eos counts were higher
in individuals reporting arthritis, heart disease, stroke, hypercholes-
terolemia, diabetes, hypertension, or metabolic syndrome than in
subjects without these disorders (Table 2). Similarly, participants
reporting these diseases had higher FeNO levels (except for stroke),
and higher CRP levels (except for hypercholesterolemia).
After multivariable adjustment, reporting heart disease, stroke,
and/or metabolic syndrome were associated with elevated B‐Eos
counts, independently of individual characteristics (age, sex,
smoking status, race/ethnicity, BMI, and height; Figure 2). B‐Eos
count was 13%, 15%, and 12% higher, respectively, in subjects
with any of these non‐respiratory diseases compared to subjects
without. Using the same variables in the model, that is, both in-
dividual characteristics and reported non‐respiratory diseases, no
independent associations were found between having a non‐
respiratory disease, and FeNO or CRP levels. Furthermore, there
was no evidence of multicollinearity among covariates in any
model (maximum VIF<2.0).
TAB L E 2 Univariate comparisons of the non‐respiratory diseases for B‐Eos, FeNO and CRP levels, in adults
B‐Eos count (/mm3) n = 15,010 FeNO (ppb) n = 6700 CRP (mg/dl) n = 11,368
Non‐respiratory diseases: Geom mean (95% CI) p‐value Geom mean (95% CI) p‐value Mean (sd) p‐value
Cancer
With 176 (169–184) 0.10 14.4 (13.5–15.2) <0.001 0.45 (0.9) 0.06
Without 170 (167–172) 12.7 (12.2–13.1) 0.37 (0.7)
Arthritis
With 176 (172–180) <0.001 13.7 (13.2–14.3) <0.001 0.50 (1.0) <0.001
Without 168 (166–171) 12.6 (12.1–13.0) 0.35 (0.6)
Heart diseases
With 191 (184–198) <0.001 15.0 (13.6–16.5) <0.001 0.50 (1.0) <0.001
Without 169 (167–171) 12.7 (12.3–13.1) 0.37 (0.7)
Stroke
With 194 (183–207) <0.001 12.6 (11.1–14.4) 0.87 0.58 (1.1) <0.001
Without 170 (167–172) 12.8 (12.4–13.2) 0.37 (0.7)
Hypercholesterolemia
With 172 (169–175) <0.001 13.2 (12.8–13.7) <0.001 0.38 (0.8) 0.61
Without 168 (165–171) 12.4 (11.9–12.9) 0.37 (0.7)
Diabetes
With 180 (176–183) <0.001 14.2 (13.7–14.7) <0.001 0.45 (0.8) <0.001
Without 167 (164–169) 12.3 (11.9–12.7) 0.35 (0.7)
Hypertension
With 179 (175–183) <0.001 14.1 (13.5–14.6) <0.001 0.47 (0.8) <0.001
Without 166 (164–168) 12.2 (11.7–12.6) 0.34 (0.7)
Metabolic syndrome
With 182 (178–186) <0.001 13.8 (13.3–14.3) <0.001 0.47 (0.8) <0.001
Without 163 (161–166) 12.6 (12.0–13.1) 0.27 (0.6)
Note: Bold values denote statistical significance at the p < 0.05 level.
Abbreviations: B‐Eos, blood eosinophil; CRP, C‐reactive protein; FeNO, fractional exhaled nitric oxide.
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3.3 | Effect of individual characteristics on B‐Eos
count in healthy control groups
After excluding children/adolescents with any respiratory disease,
and adults with any respiratory disease and at least one non‐
respiratory disease independently associated with B‐Eos count
(heart diseases, stroke, and/or metabolic syndrome), we obtained
healthy control groups with children/adolescents (n = 8944) and
adults (n = 5667), respectively (Figure 1).
The overall distribution of B‐Eos count in all the participants of
the healthy control groups, ranging from 1 to 85 years and stratified
by sex, is illustrated in Figure 3. Males show higher B‐Eos counts
compared to females across the whole age range. A decrease in B‐Eos
count was seen with increasing age in individuals <18 years, followed
by a stabilization up to around 70 years, regardless of sex. Further-
more, children/adolescents had significantly higher B‐Eos counts
than adults regardless of individual characteristics such as sex, BMI,
and race/ethnicity, except in obese individuals (Additional file 1:
Table S2).
In univariate analyses, males had significantly higher B‐Eos count
than females among both children/adolescents and adults when
analyzing absolute (Figure 4) and relative (Table 3) differences.
Furthermore, differences in B‐Eos counts were seen between
different groups of race/ethnicity; the most prominent difference was
between non‐Hispanic whites and other race/ethnicity. In adults,
being overweight or obese and being former or current smoker was
associated with higher B‐Eos counts.
In multivariate analyses, male sex, age (p = 0.025; p < 0.001 in
0–11 years and p = 0.041 in 12–17 years), being obese and being
of non‐Hispanic black or other race/ethnicity, were all indepen-
dently associated with higher B‐Eos counts in children/adolescents
(Table 3). In adults, the same factors, except age, were indepen-
dently associated with higher B‐Eos count, and being overweight
or current smoker were also independently associated with higher
B‐Eos counts. Furthermore, non‐Hispanic blacks showed lower
B‐Eos count than non‐Hispanic whites in adults. Height was a
nonsignificant factor in both age groups, and similar results were
obtained using weight instead of BMI in all models (data not
shown).
Of note, in adults where only respiratory diseases had been
excluded (n = 15,010; see Figure 1), age was independently associ-
ated with higher B‐Eos count (p < 0.001). When introducing heart
diseases, stroke, and metabolic syndrome as independent factors in
this model, the age effect was no longer significant (p = 0.290).
F I GUR E 2 Regression coefficients (ß) and 95% confidence interval of the non‐respiratory disease factors for blood eosinophil (B‐Eos),
fraction of exhaled nitric oxide (FeNO) and C‐reactive protein (CRP), in adults without respiratory diseases. Multivariate analysis adjusted for
age, sex, smoking status, race, body mass index (BMI), and height. Reference category was absence of the disease. N.A. Not applicable because
p > 0.20 in univariate analysis
F I GUR E 3 Distribution of blood eosinophil
(B‐Eos) count according to age and sex in the
combined healthy control groups. Geometric
mean and 95% confidence intervals are
presented
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F I GUR E 4 Univariate comparisons of blood eosinophil (B‐Eos) levels according to the individual characteristics of the two healthy control
groups stratified by age. Horizontal brackets are the significant differences between the categories (e.g., males vs. females). Geometric mean
and 95% confidence intervals are presented. N.A. Not applicable, because smoking status was only collected in adults. Subjects with
respiratory diseases, heart diseases, stroke, and/or metabolic disease were excluded in all groups
TAB L E 3 Univariate and multivariate
analyses of the individual factors
associated with relative changes in B‐Eos
















Male +15% <0.001 <0.001 +14% <0.001 <0.001
BMI
Normal (ref.)
Overweight +1% 0.72 0.115 +6% 0.005 0.003






+6% 0.017 0.019 −4% 0.051 0.019
Mexican/Hispanic +4% 0.050 0.49 +2% 0.37 0.76
Other +15% 0.010 0.006 +9% 0.009 0.001
Smoking status
Never smoker (ref.) NA
Former smoker NA +6% <0.001 0.10
Current smoker NA +17% <0.001 <0.001
Abbreviations: B‐Eos, blood eosinophil; BMI, body mass index.
aModel adjusted for age, sex, BMI, height, and race/ethnicity.
bModel adjusted for age, sex, BMI, height, race/ethnicity, and smoking status. ref.: reference group.
N.A. Not applicable, because smoking status was only collected in adults.
AMARAL ET AL. - 7 of 12
Figure 5 illustrates that B‐Eos count presents with a wide range
of values in healthy adults, depending on different combinations of
individual characteristics or exposures. As an example, females more
than 40 years old, having normal weight and being never smokers,
have a geometric mean of 141/mm3, whereas current smoking males
with overweight/obesity in the same age range have a geometric
mean of 200/mm3.
3.4 | Association between inflammatory markers
In both children/adolescents and adults, B‐Eos count and FeNO were
higher in those with respiratory disease, while CRP levels were not
significantly different in the two age groups (Additional file 1:
Table S3).
B‐Eos count correlated weakly with CRP in adults, both in
the healthy control group and the respiratory disease group,
whereas no correlation was found in children/adolescents (Addi-
tional file 1: Table S4). On other hand, FeNO correlated moder-
ately with B‐Eos count in children/adolescents and weakly in
adults, both in the healthy control group and the respiratory
disease group. In adults these correlations became stronger after
excluding current smokers (Additional file 1: Table S4) but was
not further modified by excluding also those using ICS treatment,
neither in adults nor children/adolescents (data not shown). FeNO
and CRP did not correlate with each other in any group
(r = −0.04–0.06, p > 0.05 all).
4 | DISCUSSION
In a large population‐based study of US participants without respi-
ratory disease we found that having heart disease, stroke, and/or
metabolic syndrome independently increased B‐Eos levels by 12%–
15%, after adjusting for covariables. No significant association was
found between any non‐respiratory disease and FeNO or CRP.
Furthermore, sex, overweight/obesity, race/ethnicity, and smoking
status were also related to B‐Eos count. Age was independently
associated with B‐Eos count only in children and adolescents.
To the best of our knowledge, this is the first study to explore the
effects of non‐disease‐related factors and non‐respiratory diseases
separately, performed in a large multiethnic population‐based sam-
ple. Furthermore, we compared B‐Eos count with FeNO and CRP
regarding the association with non‐respiratory disease.
Eosinophils play a major role in mediating allergic inflammation.
However, they have also been implicated in many other disorders,
such as specific organ damage in localized infiltrative eosinophilic
entities.43–45 In our study, having heart disease, stroke, and/or
metabolic disease were independently associated with B‐Eos count in
adults, similar to previous findings.27 This indicates that other dis-
eases than respiratory diseases must be considered when using B‐
Eos count in the management of asthma and COPD.
In spite of the correlation with B‐Eos and being well‐known and
widely used in population‐based studies as a marker of systemic
inflammation, CRP did not independently associate with non‐
respiratory diseases in our study, whereas B‐Eos count did. This
F I GUR E 5 Heatmap of the geometric mean (A) and the upper bound of the 95% confidence interval (B) of B‐Eos count, according to
specific individual characteristics in the adult healthy control group. Values presented in cell/mm3. BMI, body mass index
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suggests that an increased level of B‐Eos may better reflect the total
systemic burden of inflammation.46,47 Although elevated CRP levels
have been shown to be associated with metabolic syndrome,48,49 and
to be an independent risk factor for coronary artery disease,50,51 CRP
was in those studies not analyzed independently of individual factors
such as BMI, as was done in our study.
FeNO correlated moderately with B‐Eos count but there was a
significant independent association between non‐respiratory dis-
eases and B‐Eos count only, and not FeNO. This suggests that, even
though these two biomarkers are associated with type‐2 inflamma-
tion, they partly reflect separate inflammatory pathways, with FeNO
being a local and B‐Eos count a systemic type‐2 marker.22,52
Furthermore, FeNO did not correlate with CRP whereas there was a
correlation between B‐Eos and CRP. This indicates that B‐Eos count
but not FeNO is affected by general systemic inflammation.
The combination of B‐Eos count and FeNO could be useful to
assess different aspects of airway inflammation and to identify pa-
tients suitable for different biological agents.53 A striking example of
this is that B‐Eos count is greatly reduced by treatment with anti‐
interleukin‐5 monoclonal antibodies without any noteworthy effect
on FeNO.54,55 This might indicate that personalized cutoff values for
both B‐Eos and FeNO, adjusting for individual characteristics, could
provide improved prognostic and predictive information.
Regarding the effect of individual characteristics on B‐Eos count,
elevated B‐Eos levels have previously been described in males,27,29
current smoking27,28 and increasing age.29,30 Although we obtained
very similar results regarding sex and smoking status, age was
independently associated with B‐Eos count only in children and ad-
olescents. In adults, there is an association only if significant non‐
respiratory diseases are not excluded. After we adjust for non‐
respiratory disease factors and confirm the absence of high correla-
tions among predictor variables, age was no longer a significant
determinant of B‐Eos count in adults. There was an increase in the
prevalence of non‐respiratory disease with increasing age, corrobo-
rating that there was a relationship but no co‐linearity between non‐
respiratory diseases and age. These results suggests that the age
effect seen in previous studies was related to non‐respiratory dis-
eases commonly seen in middle‐aged and older adults. Our results
are also consistent with observations in a recent study that analyzed
a different population setting.27 The same authors also found a
similar age trend in children and adolescents, namely that subjects in
early life (≤12 years) presented the highest B‐Eos counts with an
increasing trend with decreasing age, regardless of sex. The reason
for higher B‐Eos counts in children should be studied further.
Eosinophilic inflammation has also been found to be associated
with higher BMI among adults.56 In our study, obese subjects had
higher B‐Eos values than those with normal weight. Also, current
smoking was independently associated with higher B‐Eos levels,
compared to never and former smokers. This is in line with several
studies that demonstrated a significant increase in B‐Eos counts by
smoke exposure.57 Moreover, an association between higher B‐Eos
counts and serum cotinine levels was previously reported in
healthy subjects, and even passive smoke exposure was shown to
cause elevated B‐Eos counts.26 In the same study, B‐Eos count was
higher in presently non‐exposed (serum cotinine below lower limit of
detection) former smokers compared to never smokers. However,
this could be explained by the lack of adjustment for non‐respiratory
diseases and BMI.
To our knowledge, the effect of ethnicity on B‐Eos count is
poorly evaluated in the literature. In our study, we found a race/
ethnicity influence among healthy control groups. Specifically, non‐
Hispanic white children and adolescents, and non‐Hispanic black
adults presented with the lowest B‐Eos levels. However, further
studies are needed to explore these results.
Our estimated B‐Eos levels of the adult healthy control group
were similar to those recently obtained in the same setting,29 and in
other populations without respiratory diseases,58,59 but higher than
those presented in the Hartl et al. study.27 The latter study included
subjects from a different ethnical setting than in our study, and dif-
ferences in B‐Eos count may also be explained by differences in the
cell counting methodology.
The strengths of this study were a large number of participants,
the inclusion of a broad age range and different races/ethnicities, and
that we used B‐Eos as a continuous value, rather than using pre-
defined cutoffs or median as in a previous study.27 Furthermore, we
were able to study the effects of individual characteristics, respira-
tory disease, and non‐respiratory disease separately by forming the
corresponding subgroups. We also used other clinically used in-
flammatory markers as a benchmark when studying associations with
non‐respiratory diseases.
The study also has some limitations. The cross‐sectional
design of the study, and the fact that most of the diseases were
self‐reported, may have limited the ability to support the predic-
tive properties of the markers. However, we used broad defini-
tions of respiratory disease to reduce the risk of including
individuals with true disease in healthy control groups. Moreover,
the definitions of respiratory disease that we applied have been
commonly used in NHANES reports.60,61 However, further cross‐
sectional and/or longitudinal studies that include a medical diag-
nosis of the analyzed respiratory diseases, including, for example,
lung function tests, are needed. Also, the lack of data regarding
atopy, allergic sensitization, nasal polyps, urticaria, parasitic infec-
tion, inflammatory bowel diseases, eosinophilic drug reactions and
circadian variation prevented the adjustments for these variables.
Although this is out of scope of our study aim, it should be
further explored.
In conclusion, several individual characteristics, and non‐
respiratory diseases, should be considered when interpreting B‐Eos
counts. Although FeNO has long been recognized to be influenced
by several individual factors, this marker did not associate with any
non‐respiratory disease. The individual factors that were found to
influence B‐Eos count are readily available in the clinic and could be
incorporated into novel reference equations to obtain individualized
cutoffs that would support a targeted and personalized approach in
the clinical management of chronic respiratory diseases. With the
development of new biologics that target eosinophilic airway
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inflammation, easy‐to‐use biomarkers such as the B‐Eos count need to
be better characterized to reliably predict treatment responsiveness.
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